liver cirrhosis/lafyèv

Lyen an sove nan clipboard la

Chwazi kalite sòt

14 rezilta yo

To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. Aim- To compare the efficacy of albumin when compared to placebo in the development or progression of AKI in patients with cirrhosis and spontaneous bacterial peritonitis who are at low risk for AKI development (i.e Serum Bilirubin <4 mg/dL and serum creatinine < 1 mg/dl at presentation) -

Low Dose Albumin Versus Standard Dose Albumin in Spontaneous Bacterial Peritonitis With Acute Kidney Injury.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

EUS-guided Obturation of High Risk Gastric Varices Versus Standard Endoscopic Treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This is a single-centre, pilot randomized trial study that includes 42 patients with gastric varices that will be classified according to the Sarin and Kumar classification into GOV II or IGV I with recently bleeding GV & high-risk GV (defined by Baveno VI consensus for primary

Role of EUS Guided FNA of Portal Vein Thrombus in the Diagnosis and Staging of Hepatocellular Carcinoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This is a pilot study that include 30 patients with liver cirrhosis and portal vein thrombus which don't fulfill the criteria of malignancy by imaging technique. The patients involved in the study were and will be admitted to Specialized Medical Hospital, Mansoura University Hospitals. Study

A Prospective Cohort Study to Improve HCV Care in Dialysis Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

This study is being conducted to evaluate real-world effectiveness of HCV DAA therapy in CHC hemodialysis patients when the DAA-treatment is managed and monitored by the nephrologist of hemodialysis center. Hepatitis C virus (HCV) infects an estimated 185 million individuals worldwide (1) and 3.4

Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study design and participants The study was conducted in three counties (Yucheng, Xintai and Dongchangfu) of Shandong province, China, which had the highest reported HCV case numbers in the province. Potential patients with chronic HCV infection were recruited by checking the medical records of the

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chronic hepatitis B is a long term condition caused by infection of the body with the hepatitis B virus (HBV). This infection often results in inflammation or scarring of the liver and can eventually lead to liver cirrhosis and liver failure. These infections are also one of the major causes of the

Quantification of Side Effects During Hepatitis C Therapy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatitis C Virus infection is one of the main causes of chronic liver disease worldwide with current estimates of approximately 130 - 210 million individuals (according to 3% of the world population) chronically infected with the hepatitis C virus. However, hepatitis C virus infections are among

The Efficacy of OK-432 Pleurodesis on Postoperative Air Leak

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Background and Objective] :Air leak produced after thoracic surgery is a common phenomenon.Prolonged chest tube placement can lead to empyema or infection, and extended hospitalization or even death. In 2010 many researchers reported that The incidence of lung resection produce air leak about 8-26%

Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Acute-on chronic liver failure (ACLF) was first described by Japanese researchers in 1995. In 2011, the American Association for the Study of Liver Disease (AASLD) and the European Association for the Study of the Liver (EASL) concluded that the core characteristics of ACLF were multiple organ

Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Liver cirrhosis or portal hypertension is frequently associated with congestive splenomegaly resulting in hypersplenism. Hypersplenism can be defined as anemia, leukopenia, thrombocytopenia, or a combination of these resulting from excessive, splenic sequestration or pooling of blood cells, usually

Acupuncture as an Adjunctive Treatment for Hepatitis C Patients

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background: Hepatitis C is an infectious disease affecting primarily the liver, caused by the hepatitis C virus (HCV). HCV is a worldwide problem, An estimated 130-170 million people worldwide are infected with HCV, in Israel there are an estimated 80,000 patients. Most patients infected with HCV

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is frequent because of shared modes of viral transmission. Near 20% of HIV-infected patients are also infected with HCV, the prevalence of HCV in the HIV population varying according to the route of transmission.

Postoperative Adjuvant Therapy With Recombinant Interferon-Alpha Following Curative Resection of HCC

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

1. Background Hepatocellular carcinoma (HCC) is the second commonest cause of cancer death in Hong Kong and the majority are hepatitis B related. Hepatic resection has remained the only therapeutic option that can offer these patients a chance of long-term survival. Although the safety of

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye